BREZ Overview

Business Combination Approval: Breeze Holdings Acquisition Corp. has received stockholder approval for its business combination with YD Biopharma Limited, a Taiwan-based biopharmaceutical company, and the new entity will be named YD Bio Limited, expected to trade on Nasdaq under the ticker symbol "YDES."

Company Focus and Future Plans: YD Biopharma is dedicated to developing innovative vaccines and therapeutics for infectious diseases and aims to transform treatment options for various high unmet medical needs, with the transaction expected to close within two weeks.

Proposed Merger: YD Biopharma is set to merge with Breeze Holdings Acquisition Corp., aiming for a Nasdaq listing by early 2025, with an estimated enterprise value of nearly $700 million. The merger will enhance YD Biopharma's capabilities in cancer diagnostics and therapeutics.

Recent Developments: YD Biopharma has secured patents and U.S. authorization for advanced detection technologies for pancreatic and breast cancer, expanding its product offerings and establishing a laboratory dedicated to early cancer detection.

Breeze Holdings Acquisition Corp. Trading Update: Breeze Holdings has received approval to trade on the OTCQX Best Market, with its common stock and warrants now available under the tickers "BRZH" and "BRZHW" as of August 21, 2024.

Business Combination Plans: Following the termination of a business combination with TV Ammo, Inc., Breeze intends to pursue other potential business combinations, with a deadline set by the SEC for completion by December 26, 2024.